patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1 value | histology stringclasses 3 values | stage_at_diagnosis stringclasses 3 values | driver_mutation stringclasses 7 values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2 values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6 values | overall_survival_months float64 4 83 | censored bool 2 classes | msi_status stringclasses 2 values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1 value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_408239 | REC_0000301 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 30 | 5.2 | 78 | female | 1 | 9 | 4.7 | 6 | pembrolizumab 200 mg q3w | 11 | false | MSS | 2026-03-15T05:35:56.905950+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_469226 | REC_0000302 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 26 | 3.3 | 77 | male | 2 | 7 | 5.9 | 1 | carboplatin + paclitaxel + pembrolizumab | 11.3 | false | MSS | 2026-03-15T05:35:56.906189+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_643606 | REC_0000303 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 22 | 11.5 | 75 | female | 2 | 9 | 6.1 | 5 | osimertinib 80 mg daily | 4.8 | false | MSI-H | 2026-03-15T05:35:56.906428+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_272906 | REC_0000304 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 27 | 12.9 | 65 | female | 0 | 12 | 4.3 | 1 | sotorasib 960 mg daily | 17 | true | MSS | 2026-03-15T05:35:56.906667+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_247798 | REC_0000305 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 19 | 9 | 63 | male | 0 | 17 | 6.5 | 3 | osimertinib 80 mg daily | 22.7 | false | MSS | 2026-03-15T05:35:56.906898+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_327135 | REC_0000306 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 34 | 17.3 | 59 | male | 0 | 10 | 3.4 | 4 | alectinib 600 mg BID | 15.8 | true | MSI-H | 2026-03-15T05:35:56.907130+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_673820 | REC_0000307 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 27 | 13.2 | 64 | male | 0 | 12 | 5.9 | 2 | osimertinib 80 mg daily | 28.1 | false | MSS | 2026-03-15T05:35:56.907365+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_294137 | REC_0000308 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 20 | 7.1 | 72 | female | 1 | 29 | 6.3 | 8 | entrectinib 600 mg daily | 6.6 | false | MSS | 2026-03-15T05:35:56.907593+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_461746 | REC_0000309 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 27 | 5.4 | 74 | female | 1 | 70 | 4 | 7 | pembrolizumab 200 mg q3w | 14.9 | false | MSS | 2026-03-15T05:35:56.907822+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_871603 | REC_0000310 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 24 | 4.9 | 61 | female | 1 | 17 | 5.3 | 5 | alectinib 600 mg BID | 10.3 | true | MSS | 2026-03-15T05:35:56.908052+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_569456 | REC_0000311 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 25 | 9.6 | 71 | female | 2 | 4 | 5.6 | 8 | osimertinib 80 mg daily | 14.8 | false | MSS | 2026-03-15T05:35:56.908369+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_289721 | REC_0000312 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 26 | 12.6 | 57 | female | 1 | 15 | 5.8 | 7 | entrectinib 600 mg daily | 10.8 | true | MSI-H | 2026-03-15T05:35:56.908612+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_667565 | REC_0000313 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 25 | 10.4 | 56 | male | 0 | 14 | 6 | 5 | pembrolizumab 200 mg q3w | 10.8 | true | MSS | 2026-03-15T05:35:56.908919+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_367900 | REC_0000314 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 32 | 11 | 80 | female | 2 | 6 | 3.9 | 4 | osimertinib 80 mg daily | 4.9 | true | MSS | 2026-03-15T05:35:56.909154+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_150436 | REC_0000315 | Non-small cell lung cancer | Adenocarcinoma | III | ROS1 fusion | 26 | 13.9 | 80 | female | 2 | 22 | 6.2 | 0 | entrectinib 600 mg daily | 31.4 | true | MSS | 2026-03-15T05:35:56.909392+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_832582 | REC_0000316 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 27 | 8.8 | 66 | female | 0 | 65 | 6.8 | 9 | carboplatin + paclitaxel + pembrolizumab | 11.7 | true | MSS | 2026-03-15T05:35:56.909624+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_253968 | REC_0000317 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 22 | 17.3 | 69 | female | 0 | 10 | 4.5 | 6 | alectinib 600 mg BID | 6.6 | false | MSS | 2026-03-15T05:35:56.909857+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_698268 | REC_0000318 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 25 | 12.9 | 88 | female | 1 | 14 | 5.8 | 5 | entrectinib 600 mg daily | 11.5 | false | MSS | 2026-03-15T05:35:56.910091+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_604799 | REC_0000319 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 35 | 10.4 | 71 | female | 2 | 13 | 6.1 | 2 | entrectinib 600 mg daily | 18.5 | false | MSS | 2026-03-15T05:35:56.910326+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_350416 | REC_0000320 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 30 | 5 | 60 | female | 1 | 16 | 6.7 | 2 | pembrolizumab 200 mg q3w | 21.8 | false | MSS | 2026-03-15T05:35:56.910557+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_323869 | REC_0000321 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 28 | 6.1 | 59 | female | 1 | 24 | 4.5 | 6 | carboplatin + paclitaxel + pembrolizumab | 17.1 | false | MSS | 2026-03-15T05:35:56.910788+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_281105 | REC_0000322 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 24 | 15.6 | 83 | female | 1 | 11 | 7.3 | 6 | osimertinib 80 mg daily | 9.7 | false | MSI-H | 2026-03-15T05:35:56.911021+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_948230 | REC_0000323 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 20 | 13.4 | 73 | female | 2 | 14 | 3.4 | 5 | alectinib 600 mg BID | 14.4 | false | MSS | 2026-03-15T05:35:56.911252+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_349223 | REC_0000324 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 27 | 7.9 | 71 | female | 2 | 58 | 3.5 | 1 | carboplatin + paclitaxel + pembrolizumab | 4 | true | MSS | 2026-03-15T05:35:56.911484+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_973928 | REC_0000325 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 25 | 4.7 | 77 | female | 1 | 35 | 7 | 1 | pembrolizumab 200 mg q3w | 10.1 | false | MSS | 2026-03-15T05:35:56.911717+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_714627 | REC_0000326 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 21 | 10.6 | 46 | female | 0 | 20 | 6.7 | 7 | alectinib 600 mg BID | 11.6 | false | MSS | 2026-03-15T05:35:56.912015+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_237064 | REC_0000327 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 24 | 8.5 | 73 | female | 2 | 14 | 3.8 | 4 | pembrolizumab 200 mg q3w | 9.2 | true | MSS | 2026-03-15T05:35:56.912321+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_226469 | REC_0000328 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 25 | 9.6 | 57 | female | 1 | 15 | 5.4 | 6 | entrectinib 600 mg daily | 14.6 | true | MSS | 2026-03-15T05:35:56.912560+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_684011 | REC_0000329 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 25 | 8.2 | 76 | female | 2 | 8 | 8 | 5 | osimertinib 80 mg daily | 13.6 | false | MSS | 2026-03-15T05:35:56.912797+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_323974 | REC_0000330 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 34 | 12.2 | 68 | female | 0 | 25 | 5.3 | 1 | osimertinib 80 mg daily | 13.8 | false | MSI-H | 2026-03-15T05:35:56.913028+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_361149 | REC_0000331 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 30 | 7.5 | 85 | female | 1 | 49 | 6 | 4 | pembrolizumab 200 mg q3w | 9.4 | false | MSS | 2026-03-15T05:35:56.913258+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_218815 | REC_0000332 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 13 | 5.1 | 66 | female | 0 | 29 | 6 | 4 | carboplatin + paclitaxel + pembrolizumab | 11 | false | MSS | 2026-03-15T05:35:56.913493+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_362989 | REC_0000333 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 23 | 4.1 | 70 | female | 1 | 14 | 6.8 | 8 | pembrolizumab 200 mg q3w | 4.4 | true | MSS | 2026-03-15T05:35:56.913722+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_988774 | REC_0000334 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 25 | 5.2 | 68 | female | 1 | 27 | 4.5 | 1 | carboplatin + paclitaxel + pembrolizumab | 8.3 | false | MSS | 2026-03-15T05:35:56.913954+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_300943 | REC_0000335 | Non-small cell lung cancer | Adenocarcinoma | III | KRAS G12C | 19 | 8.4 | 85 | female | 1 | 6 | 4 | 0 | sotorasib 960 mg daily | 38.6 | false | MSS | 2026-03-15T05:35:56.914196+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_936814 | REC_0000336 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 25 | 11.3 | 71 | female | 1 | 2 | 6.4 | 2 | osimertinib 80 mg daily | 18.7 | false | MSI-H | 2026-03-15T05:35:56.914448+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_902078 | REC_0000337 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 23 | 5.4 | 75 | female | 0 | 49 | 5.8 | 8 | carboplatin + paclitaxel + pembrolizumab | 6.5 | false | MSS | 2026-03-15T05:35:56.914683+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_405949 | REC_0000338 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 25 | 19.4 | 66 | male | 0 | 15 | 5.4 | 6 | alectinib 600 mg BID | 11.6 | true | MSS | 2026-03-15T05:35:56.914921+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_907088 | REC_0000339 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 20 | 15 | 72 | female | 2 | 8 | 5.8 | 2 | alectinib 600 mg BID | 21.8 | true | MSS | 2026-03-15T05:35:56.915253+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_747917 | REC_0000340 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 25 | 4.9 | 68 | female | 1 | 31 | 5.3 | 1 | pembrolizumab 200 mg q3w | 22.1 | true | MSS | 2026-03-15T05:35:56.915488+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_155984 | REC_0000341 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 20 | 7.2 | 66 | female | 0 | 38 | 3.8 | 4 | pembrolizumab 200 mg q3w | 13.2 | true | MSS | 2026-03-15T05:35:56.915717+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_258832 | REC_0000342 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 33 | 7.2 | 85 | male | 1 | 27 | 7.2 | 6 | pembrolizumab 200 mg q3w | 12.5 | false | MSS | 2026-03-15T05:35:56.915961+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_416676 | REC_0000343 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 22 | 13.8 | 84 | female | 3 | 12 | 5.5 | 5 | osimertinib 80 mg daily | 8.3 | false | MSI-H | 2026-03-15T05:35:56.916259+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_632291 | REC_0000344 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 23 | 5.3 | 56 | male | 0 | 60 | 5.2 | 6 | carboplatin + paclitaxel + pembrolizumab | 12.2 | true | MSS | 2026-03-15T05:35:56.916501+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_275952 | REC_0000345 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 22 | 11.2 | 72 | female | 1 | 23 | 3.1 | 1 | osimertinib 80 mg daily | 13 | false | MSS | 2026-03-15T05:35:56.916739+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_998350 | REC_0000346 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 31 | 4.4 | 71 | male | 2 | 16 | 7.2 | 6 | pembrolizumab 200 mg q3w | 12.5 | true | MSS | 2026-03-15T05:35:56.916972+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_170054 | REC_0000347 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 26 | 9.3 | 88 | female | 1 | 17 | 6.6 | 6 | osimertinib 80 mg daily | 7.4 | false | MSS | 2026-03-15T05:35:56.917202+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_544321 | REC_0000348 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 17 | 6.9 | 66 | female | 1 | 33 | 5.7 | 2 | carboplatin + paclitaxel + pembrolizumab | 20.5 | true | MSS | 2026-03-15T05:35:56.917431+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_363510 | REC_0000349 | Non-small cell lung cancer | Adenocarcinoma | III | ALK fusion | 25 | 13.6 | 78 | male | 2 | 2 | 5.8 | 0 | alectinib 600 mg BID | 37.5 | true | MSI-H | 2026-03-15T05:35:56.917669+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_395726 | REC_0000350 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 24 | 14.2 | 73 | female | 3 | 10 | 4.8 | 5 | sotorasib 960 mg daily | 4 | false | MSI-H | 2026-03-15T05:35:56.917907+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_341980 | REC_0000351 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 27 | 13.1 | 72 | female | 2 | 25 | 5.4 | 5 | osimertinib 80 mg daily | 17.5 | true | MSS | 2026-03-15T05:35:56.918138+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_945792 | REC_0000352 | Non-small cell lung cancer | Squamous cell carcinoma | III | None | 22 | 5.8 | 60 | female | 0 | 35 | 5 | 0 | carboplatin + paclitaxel + pembrolizumab | 31.2 | false | MSS | 2026-03-15T05:35:56.918435+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_369910 | REC_0000353 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 21 | 10.2 | 52 | male | 0 | 17 | 5 | 8 | pembrolizumab 200 mg q3w | 10.7 | true | MSI-H | 2026-03-15T05:35:56.918681+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_712503 | REC_0000354 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 28 | 10.5 | 66 | female | 0 | 21 | 7.3 | 9 | osimertinib 80 mg daily | 14.9 | true | MSI-H | 2026-03-15T05:35:56.918928+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_433523 | REC_0000355 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 28 | 2.5 | 71 | female | 2 | 10 | 7.1 | 2 | pembrolizumab 200 mg q3w | 17.8 | false | MSS | 2026-03-15T05:35:56.919163+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_183386 | REC_0000356 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 24 | 13.4 | 69 | female | 1 | 18 | 5.9 | 4 | sotorasib 960 mg daily | 13.1 | true | MSI-H | 2026-03-15T05:35:56.919395+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_475920 | REC_0000357 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 30 | 14.2 | 65 | female | 1 | 11 | 6.3 | 1 | osimertinib 80 mg daily | 24.1 | true | MSI-H | 2026-03-15T05:35:56.919632+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_648333 | REC_0000358 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 20 | 13.5 | 73 | female | 1 | 10 | 4.3 | 5 | osimertinib 80 mg daily | 8.6 | true | MSI-H | 2026-03-15T05:35:56.919864+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_182233 | REC_0000359 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 26 | 5.2 | 55 | female | 1 | 49 | 6.3 | 2 | carboplatin + paclitaxel + pembrolizumab | 4.5 | true | MSS | 2026-03-15T05:35:56.920266+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_635487 | REC_0000360 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 21 | 15.2 | 70 | female | 0 | 25 | 6 | 1 | sotorasib 960 mg daily | 23.3 | true | MSI-H | 2026-03-15T05:35:56.920577+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_226279 | REC_0000361 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 28 | 4.7 | 72 | male | 1 | 66 | 5.5 | 8 | carboplatin + paclitaxel + pembrolizumab | 11.2 | true | MSS | 2026-03-15T05:35:56.920832+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_793205 | REC_0000362 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 26 | 5.6 | 66 | female | 1 | 63 | 3.9 | 6 | carboplatin + paclitaxel + pembrolizumab | 10 | false | MSS | 2026-03-15T05:35:56.921071+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_544327 | REC_0000363 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 27 | 12.5 | 78 | female | 2 | 13 | 6.1 | 5 | sotorasib 960 mg daily | 12.2 | true | MSS | 2026-03-15T05:35:56.921309+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_183026 | REC_0000364 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 26 | 11.6 | 70 | female | 1 | 16 | 3.9 | 6 | sotorasib 960 mg daily | 16.5 | false | MSI-H | 2026-03-15T05:35:56.921549+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_397309 | REC_0000365 | Non-small cell lung cancer | Squamous cell carcinoma | III | None (PD-L1 high) | 27 | 3.9 | 66 | female | 1 | 49 | 5.9 | 0 | pembrolizumab 200 mg q3w | 33.5 | true | MSS | 2026-03-15T05:35:56.921887+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_840908 | REC_0000366 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 19 | 8.5 | 63 | female | 0 | 30 | 3.3 | 5 | entrectinib 600 mg daily | 11.5 | true | MSS | 2026-03-15T05:35:56.922129+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_463590 | REC_0000367 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 24 | 16.5 | 76 | female | 1 | 13 | 4.3 | 5 | entrectinib 600 mg daily | 7.7 | false | MSI-H | 2026-03-15T05:35:56.922366+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_360781 | REC_0000368 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 20 | 11.7 | 74 | female | 1 | 15 | 3.3 | 2 | sotorasib 960 mg daily | 4 | false | MSS | 2026-03-15T05:35:56.922603+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_139262 | REC_0000369 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 24 | 10.8 | 88 | female | 1 | 15 | 3.5 | 5 | alectinib 600 mg BID | 13.3 | false | MSS | 2026-03-15T05:35:56.922840+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_747942 | REC_0000370 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 32 | 7.3 | 68 | female | 1 | 20 | 5.7 | 4 | alectinib 600 mg BID | 5.9 | false | MSS | 2026-03-15T05:35:56.923076+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_980758 | REC_0000371 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 17 | 5.9 | 66 | male | 0 | 68 | 7.3 | 7 | carboplatin + paclitaxel + pembrolizumab | 9.4 | false | MSS | 2026-03-15T05:35:56.923312+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_573542 | REC_0000372 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 18 | 11.1 | 61 | male | 1 | 13 | 5 | 3 | alectinib 600 mg BID | 15.2 | true | MSI-H | 2026-03-15T05:35:56.923602+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_869194 | REC_0000373 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 24 | 12.2 | 70 | female | 1 | 34 | 5.2 | 6 | osimertinib 80 mg daily | 8.7 | false | MSI-H | 2026-03-15T05:35:56.923887+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_899555 | REC_0000374 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 26 | 21 | 76 | male | 3 | 13 | 8.8 | 1 | alectinib 600 mg BID | 22.9 | true | MSS | 2026-03-15T05:35:56.924246+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_467836 | REC_0000375 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 30 | 12 | 77 | female | 2 | 16 | 5.6 | 6 | osimertinib 80 mg daily | 5.1 | true | MSI-H | 2026-03-15T05:35:56.924500+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_218610 | REC_0000376 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 23 | 12.5 | 78 | female | 1 | 11 | 5.8 | 2 | sotorasib 960 mg daily | 14.4 | false | MSI-H | 2026-03-15T05:35:56.924855+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_972527 | REC_0000377 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 30 | 6.1 | 68 | female | 1 | 56 | 7.3 | 3 | carboplatin + paclitaxel + pembrolizumab | 17.7 | true | MSS | 2026-03-15T05:35:56.925087+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_156583 | REC_0000378 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 33 | 7.2 | 60 | male | 0 | 14 | 7.2 | 2 | osimertinib 80 mg daily | 14.3 | true | MSS | 2026-03-15T05:35:56.925378+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_206850 | REC_0000379 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 26 | 11.2 | 57 | male | 1 | 15 | 6.2 | 1 | osimertinib 80 mg daily | 15.4 | false | MSI-H | 2026-03-15T05:35:56.925640+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_726068 | REC_0000380 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 30 | 12.4 | 53 | male | 0 | 12 | 6.3 | 5 | osimertinib 80 mg daily | 7.8 | false | MSS | 2026-03-15T05:35:56.925891+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_263618 | REC_0000381 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 29 | 10.5 | 78 | female | 0 | 18 | 5.3 | 6 | alectinib 600 mg BID | 18.5 | false | MSS | 2026-03-15T05:35:56.926321+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_291228 | REC_0000382 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 34 | 12.4 | 63 | female | 0 | 20 | 4.9 | 2 | sotorasib 960 mg daily | 16.1 | true | MSS | 2026-03-15T05:35:56.926559+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_938219 | REC_0000383 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 30 | 16.3 | 57 | male | 1 | 13 | 6.6 | 2 | osimertinib 80 mg daily | 22.8 | false | MSI-H | 2026-03-15T05:35:56.926798+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_963183 | REC_0000384 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 21 | 15.8 | 67 | male | 0 | 14 | 6.3 | 2 | sotorasib 960 mg daily | 21.3 | false | MSS | 2026-03-15T05:35:56.927067+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_824708 | REC_0000385 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 29 | 11.9 | 71 | female | 1 | 22 | 6.8 | 2 | alectinib 600 mg BID | 18.3 | true | MSI-H | 2026-03-15T05:35:56.927304+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_891145 | REC_0000386 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 24 | 9.4 | 64 | female | 0 | 18 | 4.8 | 2 | alectinib 600 mg BID | 25.3 | true | MSS | 2026-03-15T05:35:56.927542+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_962265 | REC_0000387 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 25 | 2.6 | 62 | female | 0 | 39 | 7.5 | 7 | carboplatin + paclitaxel + pembrolizumab | 12.9 | false | MSS | 2026-03-15T05:35:56.927837+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_908366 | REC_0000388 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 28 | 8.1 | 67 | female | 1 | 9 | 8.1 | 1 | osimertinib 80 mg daily | 19.4 | false | MSS | 2026-03-15T05:35:56.928069+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_952993 | REC_0000389 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 26 | 7.1 | 55 | female | 1 | 40 | 3.8 | 7 | carboplatin + paclitaxel + pembrolizumab | 11 | false | MSS | 2026-03-15T05:35:56.928364+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_578652 | REC_0000390 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 25 | 12.2 | 80 | female | 1 | 17 | 6.5 | 2 | alectinib 600 mg BID | 10.9 | true | MSS | 2026-03-15T05:35:56.928603+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_728808 | REC_0000391 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 28 | 8.7 | 66 | male | 0 | 19 | 5.5 | 4 | osimertinib 80 mg daily | 6.8 | false | MSS | 2026-03-15T05:35:56.928929+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_205247 | REC_0000392 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 18 | 8.3 | 69 | female | 1 | 18 | 4.7 | 5 | entrectinib 600 mg daily | 6.5 | true | MSS | 2026-03-15T05:35:56.929193+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_315936 | REC_0000393 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 22 | 12.7 | 82 | female | 1 | 14 | 5.8 | 1 | osimertinib 80 mg daily | 19.6 | true | MSI-H | 2026-03-15T05:35:56.929482+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_896258 | REC_0000394 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 20 | 11.9 | 74 | male | 1 | 19 | 5.5 | 7 | sotorasib 960 mg daily | 14 | true | MSI-H | 2026-03-15T05:35:56.929733+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_227518 | REC_0000395 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 28 | 13 | 80 | female | 2 | 4 | 4.3 | 4 | osimertinib 80 mg daily | 10.4 | true | MSS | 2026-03-15T05:35:56.929970+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_225104 | REC_0000396 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 29 | 5.6 | 73 | female | 2 | 18 | 3.7 | 6 | osimertinib 80 mg daily | 6.7 | false | MSS | 2026-03-15T05:35:56.930227+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_173423 | REC_0000397 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 17 | 11.4 | 73 | female | 1 | 16 | 4.7 | 1 | entrectinib 600 mg daily | 19.4 | false | MSS | 2026-03-15T05:35:56.930463+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_650853 | REC_0000398 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 24 | 5.5 | 75 | female | 2 | 26 | 4.9 | 2 | entrectinib 600 mg daily | 17.3 | false | MSS | 2026-03-15T05:35:56.930700+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_381602 | REC_0000399 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 23 | 11.7 | 61 | female | 1 | 7 | 4.6 | 7 | osimertinib 80 mg daily | 15.5 | false | MSI-H | 2026-03-15T05:35:56.930939+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_478396 | REC_0000400 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 21 | 15.5 | 70 | female | 3 | 12 | 7.4 | 4 | sotorasib 960 mg daily | 10.9 | false | MSS | 2026-03-15T05:35:56.931173+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.